Peer-reviewed Publications

Preprint articles


  • MATOSIN N*, Arloth J, Martinelli S, Czamara D, Maitra M, Kaul D, Gassen NC, Hafner K, Müller NS, Worf K, Rehwai G, Nagy C, Scarr E, Tao R, Jaffe AE, Arzberger T, Kleinmann JE, Weinberger DR, Mechawar N, Schmitt A, Dean B, Turecki G, Hyde TM, Binder EB. Brain expressed FKBP5 delineates a therapeutic subtype of severe mental illness. Under review. Preprint:

{Peer-reviewed publications}


31. Kaul D, Schwab S.G., Mechawar N, MATOSIN N*. How Stress Physically Re-shapes the Brain: Impact on Brain Cell Shapes, Numbers and Connections in Psychiatric Disorders. Neuroscience and Biobehavioural Reviews. 2021. In press, available online 5th Feb 2021. [IF=8.460]

30. Bartlett R, Sarnyai Z, Momartin S, Ooi L, Schwab S.G., MATOSIN N*. Understanding the pathology of psychiatric disorders in refugees. Psychiatry Research. 2021. 296, 113661 [IF=2.370]


29. Kaul D, Smith C.C, Stevens J, Fröhlich A.S, Binder E.B, Mechawar N, Schwab S.G., MATOSIN N*. Severe childhood and adulthood stress associates with neocortical layer-specific reductions of mature spines in psychiatric disorders. Neurobiology of Stress. 2020. 13, 100270 [IF=7.9]

28. Niemeyer C, MATOSIN N, Kaul D, Philipsen A, Gassen NC. The role of cathepsins in memory functions and the pathophysiology of psychiatric disorders. Frontiers in Psychiatry. 2020. 11, 718 [IF=3.532]


Parental leave


27. Matosin N, Halldorsdottir T, Binder EB. Understanding the molecular mechanisms underpinning G×E interactions in psychiatric disorders: the FKBP5 model. Biological Psychiatry. 2018. 83 (10), 821-830 [IF=12.095]

26. Matosin N, Newell KA, Quidé Y, Teroganova N, Andrews JL, Green MJ, Fernandez-Enright F. Effects of common GRM5 genetic variants on cognition, hippocampal volume and mGluR5 protein levels in schizophrenia. Brain Imaging and Behavior. 2018. 12(2): 509-517. [IF=3.667]

25. Quidé Y, Matosin N, Atkins JR, Cairns MJ, Laurens KR, Jablensky A, Carr VJ, Green MJ. Common variation in ZNF804A (rs1344706) is not associated with brain morphometry in schizophrenia or healthy participants. Progress in Neuropsychopharmacology & Biological Psychiatry. 2018. 82(2): 12-20 [IF=3.689]

24. Andrews JL, Newell KA, Matosin N, Huang XF, Fernandez-Enright F. Perinatal administration of phencyclidine alters expression of Lingo-1 signaling pathway proteins in the prefrontal cortex of juvenile and adult rats. Neuronal Signaling. 2018. 2 (3): NS20180059.

23. JS Lum, SJ Millard, Frank E, Matosin N, Huang XF, Ooi L, Newell KA. Chronic Adolescent CDPPB Treatment Alters Short-Term, but not Long-Term, Glutamatergic Receptor Expression. Neurochemical Research. 2018, 43(8):1683-1691. [IF=2.125]


22. Matosin N, Cruceanu C. Stress-related memory impairments are modulated by the synergistic action of stress hormones: implications for PTSD. The Journal of Neuroscience. 2017. [5.924]

21. Matosin N, Cruceanu C, Binder EB. Preclinical and clinical evidence of DNA methylation changes in response to trauma and chronic stress. Chronic Stress. 2017. 1:1-20. [no IF]

20. Matosin N, Fernandez-Enright F, Lum JS, Newell KA. Shifting towards a model of mGluR5 dysregulation in schizophrenia: consequences for future schizophrenia treatment. Invited review, special Issue: “mGluRs: 5 years on”. Neuropharmacology. 2017. 115: 73–91. [IF=5.106]

19. Matosin N, Green MJ, Newell KA, Fernandez-Enright F. Effects of GRASP variation on memory in psychiatrically healthy individuals and cognitive dysfunction in schizophrenia. Gene Reports. 2017. 6: 121-127.

18. Cruceanu C, Matosin N, Binder EB. Interactions of early life-stress with the genome and epigenome: from prenatal stress to psychiatric disorders. Current Opinion in Behavioral Sciences. 2017. 14: 167-171. [no IF]

17. Andrews JL, Goodfellow F, Matosin N, Snelling MK, Newell KA, Huang XF, Fernandez-Enright F. Alterations of Ubiquitin Related Proteins in the Pathology and Development of Schizophrenia: Evidence from Human and Animal Studies. Journal of Psychiatric Research. 2017. 90:31-39 [IF=4.465]


16. Matosin N, Siegel SJ. mGluR5 as a point of Convergence for models of OCD and ASD. Biological Psychiatry. 2016 80:7,504–506 [IF=11.212]

15. Matosin N, Fernandez-Enright F, Lum JS, Engel M, Andrews JL, Gassen NC, Wagner KV, Schmidt MV, Newell KA. Molecular evidence of synaptic pathology in CA1 in schizophrenia. npj Nature Schizophrenia. 2016. 2: 16022 

14. Matosin N, Green MJ, Andrews JL, Newell KA, Fernandez-Enright F. Possibility of a sex-specific role for a genetic variant in FRMPD4 in schizophrenia, but not cognitive function. Neuroreport. 2016. 27(1): 33-8. [IF=1.644]

13. Lum JS, Fernandez F, Matosin N, Andrews JL, Huang XF, Ooi L, Newell KA. Neurodevelopmental expression of dimeric and monomeric group 1 mGluRs: relevance to schizophrenia pathogenesis and treatment. Nature Scientific Reports. 2016 6: 34391. [IF=5.578]

12. Engel M, Snikeris P, Matosin N, Newell KA, Huang XF, Frank E. mGluR2/3 agonist LY379268 rescues NMDA and GABAA receptor level deficits induced in a two-hit mouse model of schizophrenia. Psychopharmacology. 2016. 233(8): 1349-1359. [IF=3.875]


11. Matosin N, Fernandez-Enright F, Fung SJ, Lum JS, Engel M, Andrews JL, Huang XF, Weickert CS, Newell KA. Alterations of mGluR5 and its endogenous regulators Norbin, Tamalin and Preso1 in schizophrenia: towards a model of mGluR5 dysregulation. Acta Neuropathologica. 2015. 130(1): 119-129. [IF=10.762]

10. Matosin N, Fernandez-Enright F, Lum JS, Andrews JL, Engel M, Huang XF, Newell KA. Metabotropic glutamate receptor 5 and its trafficking molecules, Norbin and Tamalin, are increased in the CA1 hippocampal region of subjects with schizophrenia. Schizophrenia Research. 2015. 166(1-3): 212-218. [IF=4.590]

9. Wagner KV, Hartmann J, Labermaier C, Häusl AS, Zhao G, Harbich D, Schmid B, Wang X D, Santarelli S, Kohl C, Gassen NC, Matosin N, Schieven M, Webhofer C, Turck CW, Lindemann L, Jaschke G, Wettstein JG, Rein T, Müller MB, Schmidt MV. Homer1/mGluR5 signaling moderates vulnerability to chronic social stress. Neuropsychopharmacology. 2015. 40(5): 1222-1233. [IF=7.833]

8. Andrews JL, Newell KA, Matosin N, Huang XF, Fernandez-Enright F. Alterations of p75 neurotrophin receptor and myelin transcription factor 1 in the hippocampus of perinatal phencyclidine treated rats. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 2015. 63(3): 91-97. [IF=3.689]

7. Andrews JL, Newell KA, Matosin N, Huang XF, Fernandez-Enright F. NMDA receptor antagonism by phencyclidine reduces WASP and WAVE1 protein expression and reduces levels of myelination marker levels in the prefrontal cortex of ratsJournal of Pharmaceutics & Pharmacology. 2015. 3(1):8. [IF=2.264]


6. Matosin N, Fernandez-Enright F, Frank L, Deng C, Wong J, Huang XF, Newell KA. Metabotropic glutamate receptor mGluR2/3 and mGluR5 binding in the anterior cingulate cortex in psychotic and non-psychotic depression, bipolar disorder and schizophrenia: implications for novel mGluR-based therapeutics. Journal of Psychiatry & Neuroscience. 2014. 39(6): 407-16. [IF=7.492]

5. Matosin N, Frank E, Engel M, Lum JS, Newell KA. EDITORIAL  Negativity towards negative results: a discussion of the disconnect between scientific worth and scientific culture. Disease Models & Mechanisms. 2014. 7(2): 171-173. [IF=5.537]

4. Newell KA, Matosin N. Rethinking metabotropic glutamate receptor 5 pathological findings in psychiatric disorders: implications for the future of novel therapeutics. BMC Psychiatry. 2014. 14:23. [IF = 2.237]

3. Newell KA, Matosin N, Lum JS. BOOK CHAPTER Metabotropic glutamate receptors in the pathophsyiology and treatment of schizophrenia and major depression (book chapter). Metabotropic Glutamate Receptors: Molecular Mechanisms, Role in Neurological Disorders and Pharmacological Effects. Nova Publishers. 2014. ISBN: 978-1-63117-451-3


2. Matosin N and Newell KA. Metabotropic Glutamate Receptor 5 in the Pathology and Treatment of Schizophrenia. Neuroscience & Biobehavioural Reviews. 2013. 37 (3): 256-268. [IF = 10.284]

1. Matosin N, Frank E, Deng C, Huang XF, Newell KA. Metabotropic Glutamate Receptor 5 Binding and Protein Expression in Schizophrenia and following Antipsychotic Drug Treatment. Schizophrenia Research. 2013. 146 (1-3): 170-176. [IF=4.590]

Other Articles